sushma agrawal

Dr. sushma agrawal

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in South Asian Journal of Cancer
Verified
Journal Article
Open access
PDF file
SAsushma agrawal
sushma agrawal
Postoperative radiation therapy (RT) and chemotherapy,both reduces the risk of local recurrence and extends overall survival in patients with breast cancer (BC). Concerns have, however, been raised about the risk of acute and chronic side effects in breast cancer survivors as the number of treated individuals is large and their expected survival is long compared to most patients with other malignant diseases. Cardiac toxicity, reproductive dysfunction, pneumonitis (RP),arm lymph edema, neuropathy, skin changes are examples of the wide range of complications that has been associated with adjuvant treatment.

1 September 2012 in Clinical Radiology
Verified
Journal Article
Closed access
SAsushma agrawal
sushma agrawal
RAR. Awasthi
R. Awasthi
ASAnup Singh
Anup Singh
MHM. Haris
M. Haris
RGR.K. Gupta
R.K. Gupta
RRR.K.S. Rathore
R.K.S. Rathore

28 June 2013 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
STSonam Tulsyan
Sonam Tulsyan
PCPankaj Chaturvedi
Pankaj Chaturvedi
GAGaurav Agarwal
Gaurav Agarwal
PLPunita Lal
Punita Lal
SAsushma agrawal
sushma agrawal
BMBalraj Mittal
Balraj Mittal

1 June 2014 in Gene
Verified
Journal Article
Closed access
STSonam Tulsyan
Sonam Tulsyan
PCPankaj Chaturvedi
Pankaj Chaturvedi
ASAbhishek Kumar Singh
Abhishek Kumar Singh
GAGaurav Agarwal
Gaurav Agarwal
PLPunita Lal
Punita Lal
BMBalraj Mittal
Balraj Mittal

1 June 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SAsushma agrawal
sushma agrawal
LMLalit Mohan
Lalit Mohan
CMChandan Mourya
Chandan Mourya
ZNZafar Neyaz
Zafar Neyaz
RSRajan Saxena
Rajan Saxena
Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases Radiologic downstaging;neoadjuvant therapy;unresectable gallbladder cancer; Background: Gall bladder cancer (GBC) usually presents as unresectable or metastatic disease. We conducted a feasibility study to evaluate the effect of neoadjuvant therapy (NAT) on radiologic downstaging and resectability in unresectable GBC cases. Materials and Methods: Patients with locally advanced disease were treated with chemoradiotherapy [CTRT] ( external radiotherapy (45Gy) along with weekly concurrent cisplatin $35mg/m^2$ and 5-FU 500 mg) and those with positive paraaortic nodes were treated with neoadjuvant chemotherapy [NACT (cisplatin $25mg/m^2$ and gemcitabine $1gm/m^2$ day 1 and 8, 3 weekly for 3 cycles). Radiological assessment was according to RECIST criteria by evaluating downstaging of liver involvement and lymphadenopathy into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Results: A total of 40 patients were evaluated from January 2012 to December 2014 (CTRT=25, NACT=15). Pretreatment CT scans revealed involvement of hilum (19), liver infiltration (38), duodenum involvement (n=22), colon involvement (n=11), N1 involvement (n=11), N2 disease (n=8), paraaortic LN (n=15), and no lymphadenopathy (n=6). After neoadjuvant therapy, liver involvement showed CR in 11(30%), PR in 4 (10.5%), SD in 15 (39.4%) and lymph node involvement showed CR in 17 (50%), PR in 6 (17.6%), SD in 4 (11.7 %). Six patients (CTRT=2, NACT=4) with 66.6 % and 83% downstaging of liver and lymphnodes respectively underwent extended cholecystectomy. There was 16.6 % and 83.3% rates of histopathological CR of liver and lymph nodes. All resections were R0. Conclusions: Neoadjuvant therapy in unresectable gall bladder cancer results in a 15% resectability rate. This approach has a strong potential in achieving R0 and node negative disease. Radiologic downstaging (CR+PR) of liver involvement is 40.5% and lymphadenopathy is 67.5%. Nodal regression could serve as a predictor of response to neoadjuvant therapy.

2 March 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
TDTreshita Dey
Treshita Dey
SAsushma agrawal
sushma agrawal
Cervical cancer remains a significant global health challenge, ranking as the fourth most common cancer among women. Persistent infection with high-risk human papillomavirus (HPV) is the primary etiological factor, leading to immune evasion mechanisms that promote tumor development and progression. Immunotherapy has emerged as a transformative approach in the management of cervical cancer, aiming to restore and enhance the body’s immune response against tumor cells. Checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand (PD-L1) have shown promising results in patients with advanced or recurrent cervical cancer. Pembrolizumab, a PD-1 inhibitor, has been approved for PD-L1-positive cervical cancer, demonstrating durable responses. However, low response rates necessitate exploration of combination strategies. Trials are underway combining checkpoint inhibitors with chemotherapy, radiation, or other immunotherapeutic agents to enhance efficacy. Therapeutic vaccines targeting HPV antigens, such as E6 and E7 oncoproteins, are also a focus of active research. These vaccines aim to elicit robust cytotoxic T-cell responses, offering a potential strategy for early intervention and disease control. Adoptive T-cell therapies, including engineered T-cell receptor (TCR) and chimeric antigen receptor (CAR)-T cells, represent cutting-edge advancements, though challenges with tumor heterogeneity and off-target effects persist. However, challenges such as limited response rates and immune evasion mechanisms remain. The tumor microenvironment (TME) in cervical cancer, characterized by immunosuppressive cells and cytokines, poses a significant barrier to effective immunotherapy. Emerging approaches targeting the TME, such as cytokine modulation, hold promise in overcoming resistance mechanisms. Key gaps include a lack of biomarkers for patient selection, insufficient understanding of TME dynamics, and suboptimal strategies for overcoming antigen heterogeneity and immune resistance. This review addresses these issues by providing a comprehensive analysis of the current landscape of cervical cancer immunotherapy, identifying critical barriers, and highlighting emerging approaches, such as combination therapies, novel immune targets, and strategies to modulate the TME, to guide future research and clinical practice.